Drugs / upifitamab rilsodotin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04907968 | Jun 2021 → Oct 2023 | — | Mersana Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT06517485 | Jul 2019 → May 2022 | lung adenocarcinoma, refractory malignant neoplasm | Mersana Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06517433 | Dec 2017 → Jul 2021 | non-small cell lung carcinoma, refractory malignant neoplasm | Mersana Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03319628 | Dec 2017 → May 2023 overdue | non-small cell lung carcinoma, refractory malignant neoplasm | Mersana Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Upifitamab Rilsodotin | “XMT-1536 (Upifitamab Rilsodotin)” NCT04907968 ↗ |
| Known as | XMT-1536 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04907968 ↗ |
| Modality | Other / unclassified | “antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin)” NCT06517433 ↗ |
| Route | Intravenous | “administered as an intravenous infusion once every four weeks.” NCT03319628 ↗ |